CAS: 132123-54-7; 3,4,5-Trifluorobenzaldehyde

相似化合物

220227-37-2 121602-93-5 134227-45-5

上下游产品

orthoformic acid triethyl ester 3,4,5-trifluoro-1-bromobenzene N,N-dimethyl-formamide (E)-3-(3,4,5-trifluorophenyl)acrylaldehyde 1,2,3-Trifluoro-5-((1E,3E)-4-phenyl-buta-1,3-dienyl)-benzene 9-(3,4,5-trifluorophenyl)-6,9-dihydro[1,3]dioxolo[4,5-g]furo[3,4-b]quinolin-8(5H)-one (E)‐3‐(3,4,5‐trifluorophenyl)acrylic acid

N,N-二甲基甲酰胺,3,4,5-三氟溴苯置于magnesium体系中,用 四氢呋喃 用作溶剂,化学反应 2.0H,以37.91 G的收率获得3,4,5-三氟苯甲醛
参考文献:Us2014/275577
标题:Us2014/275577

专利信息

专利号:WO-9967219-A1
优先权日:1998-06-22
标 题:Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
发明人：AUDIA JAMES E; PORTER WARREN J; THOMPSON RICHARD C; WILKIE STEPHEN C; STACK DOUGLAS R; SHI QING
权利人:ELAN PHARM INC; LILLY CO ELI; AUDIA JAMES E; PORTER WARREN J; THOMPSON RICHARD C; WILKIE STEPHEN C; STACK DOUGLAS R; SHI QING
摘要:Compounds of formula (I), wherein W is a cyclic group of the type (2); (3); Y is represented by the formula (II); these compounds inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

专利号:US-6838455-B2
优先权日:1998-06-22
标题 :Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
发明人：AUDIA JAMES E; PORTER WARREN J; THOMPSON RICHARD C; WILKIE STEPHEN C; STACK DOUGLAS R; SHI QING
权利人:ATHENA NEUROSCIENCES INC; LILLY CO ELI
摘要:Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

专利号:US-2009306392-A1
优先权日:2007-10-19
标题 :Gsm intermediates
发明人：HO CHIH YUNG
权利人:HO CHIH YUNG
摘要:The present invention relates the use of compounds having the general Formula I, wherein the definitions or R 1 and R 2 are provided in the specification. Said compounds of Formula I are useful for the synthesis of a variety of γ-secretase modulators, which are in turn useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.

专利号:US-6852711-B2
优先权日:1998-09-11
标题:HIV protease inhibitors
发明人：BOYER JR FREDERICK EARL; DOMAGALA JOHN MICHAEL; ELLSWORTH EDMUND LEE; GAJDA CHRISTOPHER ANDREW; HAGEN SUSAN ELIZABETH; LOVDAHL MICHAEL JAMES; LUNNEY ELIZABETH ANN; MARKOSKI LARRY JAMES; PRASAD JOSYULA VENKATA NAGENDR; TAIT BRADLEY DEAN
权利人:AGOURON PHARMA
摘要:The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

专利号:EA-032052-B1
优先权日:2014-09-25
标 题 :METHOD OF CHIRAL SYNTHESIS OF N-ACYL- (3-SUBSTITUTED) - (8-SUBSTITUTED) -5,6-DIHYDRO- [1,2,4] TRIAZOLO [4,3-a] PYRAZINES

专利号:US-6172066-B1
优先权日:1996-05-16
标 题:Dihydropyrimidines and uses thereof
发明人：NAGARATHNAM DHANAPALAN; WONG WAI C; MIAO SHOU WU; PATANE MICHAEL A; GLUCHOWSKI CHARLES
权利人:SYNAPTIC PHARMA CORP
摘要:This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the α 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.